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Abstract An available supply of intravenous immuno-
globulin (IVIG) is essential for individuals with primary
humoral immunodeficiency. A shortage in 1997 prompted
the Food and Drug Administration (FDA) to revise
guidelines for the licensure, production, and distribution of
new IVIG products, including the standardization of United
States clinical trials regarding endpoints for safety, effi-
cacy, and pharmacokinetics. The following review is
intended to present current information and results of
clinical trials in patients with primary immunodeficiency
treated with IVIG products currently licensed or awaiting
licensure in the United States. The data presented are
compiled from published clinical trials and prescribing
information generated by manufacturers.
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Introduction
In the Fall of 1997, increased demand, reduced supply, and
product recalls created a shortage of intravenous immu-
noglobulin (IVIG) in the United States. Key factors in the
shortfall in production included issues of regulatory com-
pliance and good manufacturing practices. In response, the
Food and Drug Administration (FDA) facilitated produc-
tion and distribution, shortened the review of lot release
protocols, expedited the review of license applications, and
streamlined clinical trial design.
At the FDA Blood Products Advisory Committee
(BPAC) meeting held in March, 1999 [1], the FDA rec-
ommended a change in design for a pivotal clinical trial to
evaluate the safety and efficacy of a new IVIG product.
The new design involved a prospective, randomized, dou-
ble-blind, parallel-group, positive-controlled, non-inferior-
ity study in 80 subjects with a documented history of
primary immune deficiency, in which the safety and effi-
cacy of the test product was to be compared head-to-head
to a US-licensed IVIG product. Investigational new drug
(IND) sponsors would evaluate efficacy by comparing the
serious infection rate in each randomization group over an
observation period of 12 months.
Following the March 1999 BPAC meeting, the FDA
increasingly recognized several problems with this trial
design, e.g., limited numbers of patients that could be
recruited for trials, multiple new IVIG products to be tes-
ted, and the potential for IVIG shortages. At the March
2000 BPAC meeting [2], the FDA presented an alternate
clinical trial design for the evaluation of IVIG safety and
efficacy in primary immune deficiency (PID). The new
proposal was a single-arm, 12-month, open study of
approximately 50 PID patients with safety and efficacy
targets based on previous trials. Pharmacokinetic studies
would be performed on at least 20 PID patients and
observed values should not be inferior to those previously
determined for approved products.
Since 1999, the FDA has issued two guidance docu-
ments for clinical trials of IVIG to support the marketing of
IVIG as replacement therapy for primary humoral defi-
ciency [3, 4]. The 2005 FDA Guidance [3] defined the
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primary efficacy endpoint as the rate of acute serious
bacterial infections (SBIs) during the year of treatment
with the study IVIG. Based on the FDA’s examination of
historical data, the SBI rate was to be\1.0 per subject per
year at the 0.01 level of significance. SBIs were defined as
bacteremia/sepsis, bacterial meningitis, osteomyelitis/sep-
tic arthritis, bacterial pneumonia, and visceral abscess.
Essential diagnostic features for each infection were
described.
Safety endpoints were the overall incidence of adverse
events (AEs) (regardless of causality) that occurred during
or within 1, 24, and 48 h after infusion of the test prod-
uct. Temporally associated AEs are those that occurred
during infusion and up to 48 h after infusion. A primary
endpoint was to record the proportion of infusions with
one or more temporally associated AEs (including AEs
that were determined to be unrelated to the product). The
target for this endpoint was an upper one-sided 95 %
confidence limit of \0.40 [3]. The number of subjects to
achieve the suggested endpoints was estimated at 40–50
subjects.
The 2008 FDA Guidance [4] extended the time period
for temporally associated AEs to 72 h and added instruc-
tions for conducting pharmacokinetic studies in pediatric
patients.
The effect of the 2005 and 2008 Guidances has been to
standardize endpoints for safety, efficacy, and pharmaco-
kinetics in clinical trials conducted in the United States
over the last decade. We report here the results of clinical
trials in patients with primary immunodeficiency treated
with IVIG products currently licensed in the United States.
Early studies
In 1890, Emil Behring and Shibasaburo Kitasato discov-
ered that the injection of guinea pigs with sterilized cul-
tures of diphtheria or tetanus bacilli produced substances in
the sera that could neutralize diphtheria or tetanus toxins.
They further showed that sera produced in one animal
could be used to cure infected animals and to protect
healthy animals from diphtheria or tetanus infection mor-
tality [5, 6].
In the 1930s, Enders showed that normal human serum
could prevent measles [7]. Contemporary attempts to
concentrate this activity in the gamma globulin fraction
often resulted in bacterial contamination and adverse
reactions in recipients [7]. The use of cold ethanol frac-
tionation as a means to isolate gamma globulin from
human plasma finally provided a consistently safe material
for injection [7–9]. This material, Cohn Fraction II, was
shown by Enders to contain the majority of anti-measles
activity [7].
In 1952, Bruton treated a child that had undetectable
gamma globulin levels and recurring pneumococcal
infections with subcutaneous infusions of human immune
serum globulin (ISG, i.e., Cohn Fraction II formulated at
165 mg/mL). The injection of 3.2 g/month ISG increased
circulating gamma globulin levels and completely elimi-
nated pneumococcal infections [10]. These observations
were rapidly confirmed [7] and treatment with human IgG
soon became the standard of care for patients with primary
antibody deficiencies [7].
Early clinical studies of ISG were conducted primarily
in children who suffered from recurrent bacterial infec-
tions, exhibited evidence of deficient antibody production,
and had extremely low levels of circulating gamma glob-
ulin [11]. ISG was restricted to intramuscular injection
because intravenous injection caused severe pyrogenic and
cardiovascular reactions in many recipients [12]. In
response, a series of manufacturing changes designed to
reduce the incidence of side effects led to the development
of immune globulins intended for intravenous injection
(IVIG).
Spontaneous complement activation (anti-complement
activity) by IgG aggregates was considered to be the
principal cause of adverse reactions [13]. To suppress anti-
complement activity, some manufacturers treated Cohn
Fraction II with enzymes or chemical modification.
Unfortunately, these treatments also reduced important
antibody biological activities required for clinical efficacy
and shortened IgG circulating half-lives [14–16].
The recognition that Cohn Fraction II contained trace
amounts of highly active contaminants such as prekalli-
krein activator, prekallikrein, and activated coagulation
factors led to the development of Cohn Fraction II purifi-
cation procedures using anion (DEAE) exchange chroma-
tography. The first DEAE-purified IVIG contained none of
the trace contaminants associated with AEs and some
antibody biological activities, such as bacterial opsoniza-
tion and virus neutralization, were higher than in ‘‘treated’’
products [17]. Most commercial IVIGs are now produced
with an anion exchange chromatography step and contain
relatively low levels of trace contaminants.
In the 1980s, the licensure of IVIG in the United States
was generally based on data from relatively small numbers
of PID patients. The first IVIG licensed in the United States
was chemically modified. Twenty patients with X-linked
agammaglobulinemia (XLA, n = 9) or common variable
immunodeficiency (CVID, n = 11) were randomized to
receive either 150 mg/kg/4 weeks of IVIG or 100 mg/kg/
4 weeks of ISG. Fourteen patients were treated with IVIG
for 242 treatment months. This group developed 0.103
acute infections/month of treatment. In contrast, 13 patients
treated with ISG for 193 treatment months developed 0.295
acute infections/month of treatment [18].
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Cunningham-Rundles et al. [19] studied 21 patients who
were treated with 300 mg/kg IVIG every 3 weeks for 1 year
following a year of treatment with ISG. In the 18 patients
who completed a year of IVIG treatment, the average IgG
trough level was 505 mg/dL, compared to 262 mg/dL
during ISG treatment. Efficacy endpoints such as days of
illness from infection (e.g., upper respiratory tract infec-
tions, bronchitis, sinusitis, etc.) were significantly lower
(p \ 0.001) during the IVIG treatment year compared to the
ISG treatment year. Adverse reactions to IVIG were
observed in 10 of 407 infusions (2.5 %) and were elimi-
nated by slowing or temporarily stopping the infusion [19].
In a trial of another IVIG, Ochs et al. treated 15 PID
patients with 400 mg/kg every 4 weeks for 1 year. Twenty-
one adverse reactions were associated with 15 of 341
infusions (4.4 %) during the first 48 h after infusion. The
incidence of acute upper respiratory infections was as low
or lower than infections reported for other preparations [20].
In a third trial, Roifman and Gelfand compared high-
versus low-dose therapy in patients with hypogammaglob-
ulinemia and sinopulmonary disease. High-dose therapy
(600 mg/kg every 4 weeks) proved efficacious in reducing
symptoms, decreasing the frequency of major and minor
infections, and significantly improving pulmonary function.
The improvement appeared to correlate with a marked
reduction in the isolation of Mycoplasma, particularly Ure-
aplasma urealyticum, an important cause of infection in
patients with hypogammaglobulinemia [21].
Recent studies in the United States
The following studies reflect the evolution of FDA Guidance
documents for testing the safety and efficacy of intravenous
immune globulins to be marketed in the United States.
Gamunex 10 %
One IVIG was studied using the 1999 BPAC trial design
[22]. Twenty-five centers in the US and Canada enrolled 172
patients with PID who were already receiving IVIG
replacement therapy. Patients, aged 1–75 years, were ran-
domly assigned to treatment for 9 months with either
investigational IVIG (Gamunex 10 %, n = 87) or the US
licensed control IVIG (Gamimune N 10 %, n = 85).
Seventy-three per-protocol patients in each treatment group
were evaluated for efficacy. The primary endpoint was the
proportion of patients with at least one validated acute
sinopulmonary infection during the 9-month treatment per-
iod. Diagnostic criteria for validated infections were defined
prospectively. Secondary endpoints were the incidence of all
infections, time to first infection, lung function parameters,
infusion-related safety, and viral safety [22].
Patient demographics and disease characteristics were
essentially the same in each group (Table 1). Validated
infections occurred in 9 (12.3 %) patients treated with
Gamunex 10 % and 17 (23.3 %) patients treated with
Gamimune N 10 %. AE rates within 48 h were very similar
in each group. No serious adverse events (SAEs) were
reported. Direct Coombs tests (also known as direct anti-
globulin tests or DAT) were transiently positive in 29/87
patients (33 %) in the Gamunex 10 % group and 16/85
patients (19 %) in the Gamimune N 10 % group. No
clinical or laboratory evidence of hemolysis was detected
in the DAT-positive patients [22]. The IgG half-life was
35 days in patients treated with Gamunex 10 % and
34 days in Gamimune N 10 % recipients [23].
Octagam 5 %
Octagam 5 % was the first IVIG studied using the 2000
BPAC trial design. Forty-six PID patients at nine clinical
sites were treated for 12 months with 300–450 mg/kg IVIG
every 21 days or 400–600 mg/kg every 28 days [24]. The
primary efficacy endpoint was the rate of serious infections
per patient per year and a requirement that the annual rate
be \1 serious infection/patient/year. Serious infections
were defined prospectively as pneumonia, bacteremia or
sepsis, osteomyelitis or septic arthritis, visceral abscess,
and bacterial or viral meningitis.
All 46 patients received at least one infusion of the study
IVIG and were included in the study analysis. They ranged
in age from 6 to 74 years (mean = 31). The underlying PID
diagnoses were CVID in 28 patients (61 %) and XLA in 13
patients (28 %). Nineteen patients received IVIG infusions
every 21 days and 27 were infused every 28 days [24].
Three patients experienced five serious infections. One
patient had one episode of pneumonia and two infections
were recorded as bacteremia or sepsis infection. The
remaining two patients experienced one bacteremia or
sepsis infection each. The overall serious infection rate was
0.1 serious infection/subject/year. Thirty subjects (65 %)
missed one or more days of work or school; four subjects
were hospitalized at least once because of pneumonia,
severe cellulitis, severe upper abdominal pain, or gastro-
enteritis, and twenty-seven subjects visited a physician or
emergency room (ER) at least once (also see Table 1). The
IgG half-life was 41 ± 17 days. As shown in Table 2, 12
SAEs were recorded in six patients. None were related to
the study IVIG [24].
Gammagard Liquid 10 %
Using the same basic study design, Gammagard Liquid
10 % was evaluated in 61 adults and children with PID in
an open-label, historically controlled, single-arm clinical
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trial. The primary efficacy endpoint was the incidence of
acute SBIs per subject per year, with a target of B1.0 SBIs
per subject per year. SBIs were defined prospectively as
bacterial pneumonia, bacteremia/sepsis, osteomyelitis/sep-
tic arthritis, visceral abscess, and bacterial/meningitis, all
of which were required to meet specific diagnostic criteria.
Secondary efficacy endpoints were the rate of predefined
non-SBIs that commonly occur in PID patients and the
number of hospitalizations resulting from infections [25].
Subjects were to be treated every 21 or 28 days with
300–600 mg/kg of the study IVIG for 12 months. The
majority of subjects (41 of 61, 67.2 %) were diagnosed
with CVID or hypogammaglobulinemia. Five patients had
XLA and one of each had ataxia telangiectasia, severe
combined immunodeficiency, IgG subclass deficiency,
combined IgG/CD40 deficiency, and hyper IgE syndrome.
The diagnosis of 10 subjects was recorded as PID [25].
No acute SBIs were reported. The 95 % confidence
interval for the incidence of acute SBIs was 0–0.060. Four
patients experienced non-SBIs that commonly occur in PID
subjects at a rate of 0.07 infections/patient/year. A total of
224 non-serious infections that were not predefined were
also recorded with an incidence of 3.4 infections/subject/
year [25].
Fifty-seven subjects were included in the pharmacoki-
netic study. The median IgG half-life was 35 days (see
Table 1). The median trough IgG levels varied from 960 to
1,120 mg/dL. The median IgG Cmax was 2,050 mg/dL and
the median Cmin was 1,030 mg/dL. A total of 826 infusions
of Gammagard Liquid 10 % were administered during the
study. The median dose per patient was 455 mg/kg (range
262–710 mg/kg) [25].
Two SAEs (both aseptic meningitis) occurred in one
patient and were judged to be related to the study product.
Of the 896 non-SAEs, 258 (28.8 %) were possibly or
probably related to infusion of the study product. There
were 345 temporally associated AEs, i.e., that occurred
during or within 72 h of a study infusion. The most fre-
quent temporally associated AEs were headache (22 % of
patients), fever (13 % of patients), and fatigue (10 % of
patients). Headache was the only AE associated with more
than 5 % of infusions (6.9 %) [26].
Flebogamma 5 % DIF
Flebogamma 5 % DIF (dual inactivation and filtration)
IVIG was studied in an open-label, historically controlled
clinical trial that followed the 2005 FDA Guidance [3].
Flebogamma 5 % DIF was administered to 50 PID
patients at doses of 300–600 mg/kg every 21–28 days for
12 months. The patients ranged in age from 15 to 75 years
(mean, 38.9 years); 29 (63 %) were male; 35 patients were
diagnosed with CVID and 10 with XLA. Thirteen patients
were treated every 21 days and 33 were treated every
28 days [27].
Forty-six patients completed the study. All 50 patients
received at least one infusion of the study product and were
analyzed for safety. One patient experienced one episode of
bacterial pneumonia that resulted in an overall SBI rate of
0.021 SBI/patient/year, with an upper 98 % confidence
limit of 0.112 SBI/patient/year. Secondary efficacy end-
points are summarized in Table 1. Twenty-three patients
(50 %) missed at least 1 day of work/school. The median
number of days of work/school missed per subject per year
was 0.5 days and the mean was 13 days (range
0–257 days). Twenty-nine patients (63 %) visited a phy-
sician or the ER at least once for a visit not scheduled as
part of the study [27].
The pharmacokinetics of IgG and specific antibodies
were studied in eight patients who were treated every
21 days and 12 who were treated every 28 days. In the
21-day patients, the IgG half-life was 30 ± 9 days, the
half-life of five serotypes of S. pneumoniae ranged from 14
to 16 days, and the half-life of tetanus antibody was
28 ± 13 days. In the 28-day patients, the IgG half-life was
32 ± 5 days, the half-life of five serotypes of S. pneumo-
niae ranged from 14 to 16 days, and the half-life of tetanus
antibody was 24 ± 13 days. IgG trough levels were
[900 mg/dL (Table 1) [27].
Forty-three subjects reported at least one AE. There
were 144 infusions (20.1 %, 95 % confidence limit
24.4 %) associated with one or more AEs that began within
72 h of infusion. There was one severe AE (hives), but no
SAEs. Excluding infections, the most frequent AE was
pyrexia (37 % of subjects), headache (35 % of subjects),
and wheezing (22 % of subjects) [28].
Privigen
Utilizing the study design described in the 2005 FDA
Guidance, Privigen, a 10 % liquid IVIG, was adminis-
tered to 80 PID patients. Of these, 59 (73.8 %) were
diagnosed with CVID and 21 (26.6 %) with XLA [29]. The
study patients, ages 3–69 years, were treated for 12 months
with 200–888 mg/kg of Privigen every 21 days (n = 16)
or 28 days (n = 64). Seventy-two patients completed the
study (per-protocol population). Of the eight patients who
discontinued, four withdrew consent, three discontinued
because of AEs, and one died. Six patients experienced an
SBI—three cases of pneumonia and one case each of septic
arthritis, osteomyelitis, and visceral abscess. The annual
SBI rate was 0.08 for the ITT population (upper one-sided
97.5 % confidence limit = 0.182). Sixty-six (82.5 %)
patients experienced a total of 255 infections (including
SBIs) for an annual rate of 3.55 per patient. The most
prevalent infections were sinusitis (31.3 % of patients),
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nasopharyngitis (22.5 % of patients), and upper respiratory
infections (22.5 % of patients) [29, 30].
Fifty-three patients (66.3 %) missed work/school or
were unable to perform normal activities because of illness,
resulting in an average annual rate of 7.94 days per patient.
There were five patients who missed C30 days each. Fif-
teen patients were hospitalized for 166 days (two patients
were hospitalized for 116 days), for an annual rate of 2.31
hospitalization days per year [29, 30].
The pharmacokinetics of IgG and IgG subclasses were
studied in three patients who were treated every 21 days
and 22 patients who were treated every 28 days. The
median IgG half-life in all subjects was 36.6 days.
The percentage of infusions with temporally associated
AEs related to the study IVIG was 9 %. The percentage of
infusions with one or more temporally associated AEs was
20.8 % (upper 97.5 % confidence limit = 23.8 %). Head-
ache (43.8 % of patients), pain (25.0 %), and fatigue
(16.3 %) were the AEs reported most often. Sixteen
patients (20 %) experienced 38 SAEs. An 11-year-old girl
had a hypersensitivity reaction during her second infusion
and five SAEs were recorded (hypersensitivity, chills,
fatigue, dizziness, and fever). The patient was withdrawn
from the study. One patient, diagnosed with lymphopro-
liferative disorder 6 months into the study, died from
associated multisystem organ failure [29, 30].
The direct Coombs test (DAT) changed from negative at
baseline to positive after the first or second infusion of the
study IVIG in 33 of 77 (42.9 %) patients. No subjects
exhibited evidence of hemolytic anemia [22].
Flebogamma 10 % DIF
Flebogamma 10 % DIF was studied in an open-label,
historically controlled clinical trial that followed the 2008
FDA Guidance. Subjects with PID were enrolled at six
sites in the US and were treated for 12 months with
300–600 mg/kg of the study IVIG every 21 or 28 days.
Nineteen patients participated in the pharmacokinetic study
of IgG, IgG subclasses, five S. pneumoniae serotypes, tet-
anus antitoxoid, cytomegalovirus (CMV) antibody, and
hepatitis B surface antibody (anti-HBV) [31].
One patient suffered one episode of bacterial pneumonia
for an annual SBI rate of 0.025/patient/year. The inci-
dences of other efficacy endpoints are listed in Table 1.
Non-SBIs documented by positive radiograph or fever
occurred in 15 % of patients. Overall, 28 patients reported
at least one infectious episode, producing a mean incidence
of 2.2 infections per patient per year. Thirty-six patients
(78 %) received at least one course of antibiotic therapy
and 19 patients (41 %) received at least one course of
antibiotic prophylaxis. Twenty subjects (43 %) missed one
or more days of work/school/normal activities. Five
patients were hospitalized at least once. Twenty-four sub-
jects (52 %) made one or more unscheduled ER or urgent
care visits [31, 32].
The half-life of IgG was 34 ± 10 days in the 21-day
patients (n = 10) and 37 ± 13 days in 28-day patients
(n = 9). The half-lives of IgG subclasses were similar to
that of IgG, but higher variability was observed. For the
21-day subjects, the half-lives of S. pneumoniae serotypes
4, 6B, 9V, 14, and 19F ranged from 23 ± 10 to
29 ± 20 days; for the 28-day subjects, the values ranged
from 24 ± 6 to 36 ± 33 days. The half-life of antibody to
tetanus toxoid was 22 ± 7 days in both groups. The half-
lives of antibodies to CMV and HBV were of the same
order of magnitude as total IgG [31, 32].
Three patients experienced four SAEs that were unre-
lated to the study IVIG and one patient experienced four
SAEs related to infection. No SAEs were considered to be
related to the study IVIG. There were no deaths. Three
subjects withdrew from the study because of AEs. Forty-
five (98 %) patients experienced one or more AEs irre-
spective of the relationship to the study product, for a total
of 723 AEs. Thirty-eight subjects (83 %) had a product-
related AE. Flebogamma 10 % DIF infusions associated
with one or more AEs during or within 72 h was 36.7 %,
with an upper one-sided 95 % confidence limit of 43.9 %.
The most frequent temporal AEs were headache (52 % of
subjects), rigors (37 % of subjects), and pyrexia (33 % of
subjects) [31, 32].
Forty-three of the 46 subjects enrolled in this study had a
negative Coombs test at baseline. Of these, 10 (23.3 %)
developed a positive Coombs test during the study. No
subjects showed evidence of hemolytic anemia [31, 32].
Gammaplex
Gammaplex is a 5 % liquid IVIG that was studied in an
open-label clinical trial designed according to the 2005
FDA Guidance. Fifty subjects were enrolled at seven
centers; 22 were infused every 21 days and 28 were infused
every 28 days. Patients received 279–799 mg/kg of the
study IVIG per infusion. Forty-five subjects completed the
study. Two patients were discontinued because of an AE,
one subject was discontinued because of pregnancy, one
was lost to follow up, and another withdrew consent [33].
The patient demographics are shown in Table 1. Six
subjects (12 %) had at least one SBI in the 6 months before
enrollment. However, there were no SBIs during the study.
Thus, the mean SBI rate/year was zero, with an upper one-
sided 99 % confidence limit of 0.101. Forty subjects (80 %)
had at least one non-serious infection, with a mean rate of
3.28 infections/subject/year. Therapeutic antibiotics were
administered to 40 subjects (annual rate of 47.2 days/sub-
ject/year). Thirty-three courses of prophylactic antibiotics
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were given to 16 patients, seven of whom were on pro-
phylactic antibiotics throughout the entire study. Twenty-
three patients (46 %) missed 394 days of work or school
because of infection or other illness, for an annual rate of
8.73 days/patient/year [34]. Four patients were hospitalized
for 29 days, producing an annual rate of 0.75 hospitaliza-
tion days/subject/year [33].
All 50 subjects had at least one AE. Twenty-four sub-
jects (48 %) had a product-related AE. The 21-day subjects
had more product-related AEs (14/22, 64 %) than the
28-day subjects (10/28, 36 %). The total number of tem-
porally associated AEs (0–72 h) was 237 (0.34 AEs per
infusion). Of the 703 infusions administered, 21 % were
associated with one or more temporally associated AEs.
The upper one-sided 97.5 % confidence limit was 24 %. Of
the 237 temporally associated AEs, 115 (49 %) were
judged to be product-related. Headache was the most
common product-related AE (7.5 % of 703 infusions) [33].
Five subjects (10 %) experienced seven SAEs. Two of
the SAEs were considered to be related to the infusion of
Gammaplex (thrombosis and chest pain) [33].
Forty-seven of the 50 subjects enrolled in this study had
a negative DAT at baseline. Four subjects (8.5 %) devel-
oped a positive DAT during the study. No subjects showed
evidence of hemolytic anemia [33].
Pharmacokinetics were assessed in nine subjects on the
21-day infusion schedule and 15 subjects on the 28-day
infusion schedule. The IgG half-life was 42 ± 26 days in
the 21-day patients and 41 ± 14 days in the 28-day
patients [34].
Biotest-IVIG
Biotest-IVIG, a 10 % liquid IVIG, was studied in an open-
label, phase III trial that followed the 2005 FDA Guidance.
The primary efficacy endpoint was to demonstrate that the
rate of acute SBIs was \1.0 per person/year. Secondary
efficacy parameters included infections of any kind or
severity, time to the first infection of any kind, time to first
SBI, days missed from school or work due to infection,
days on antibiotics, hospitalizations, and days of hospital-
ization due to infection [35].
Sixty-three patients were enrolled, treated with 746
infusions of Biotest-IVIG (300–800 mg/kg), and included
in the population evaluated for safety. Seventeen patients
were infused every 3 weeks and 46 were infused every
4 weeks. Of the 63 enrollees, 51 patients completed the
study. The most common immunodeficiency diagnosis was
CVID (81 % of patients). The average age was 41.2 years
(range 6–75 years). Eight patients had a history of acute
SBIs prior to study entry [35].
Two SBIs occurred during the 53.54 person-years of the
study, resulting in an incidence of 0.037 SBI/patient/year,
with an upper 99 % confidence limit of B0.101 SBI/
patient/year. Twenty-one patients (33 %) missed 122 days
of work or school because of infection, resulting in a rate of
2.28 days/patient/year. Thirty-eight patients (60 %) were
treated with therapeutic antibiotics for 1,812 days, for a
rate of 39.1 days of therapeutic antibiotics/patient/year
[35].
A total of 937 AEs were recorded in the 63 patients in
the safety population. 339 (36 %) of the AEs occurred in
six patients. Fifty-nine patients (94 %) reported at least one
AE. Of these, 40 patients (64 %) experienced an AE that
was related to study product. The most frequent severe AEs
considered to be related to the study drug were headache
(3 patients, 4.8 %) and migraine and fatigue (2 patients,
3.2 % each). Eleven SAEs were reported in seven (11 %)
patients. Two of the SAEs (vomiting and dehydration) that
lead to the hospitalization of one patient were considered to
be related to the study product. There were no deaths [35].
There were 431 temporally associated AEs in 47 (75 %)
patients. The proportion of infusions with one or more
temporally associated AEs, regardless of the relationship to
the study product, was 27.7 %, with an upper one-sided
95 % confidence limit of B30.6 %. The most frequent
temporally associated AE was headache (115 infusions in
27 patients), followed by fatigue (59 infusions in 15
patients) [35].
The pharmacokinetics population was composed of 5
patients in the 3-week infusion group and 16 patients in the
4-week group. The IgG half-life for the total population
was 30 ± 11 days, with a range of 16.2–51.6 days. The
half-lives of specific antibodies ranged from 25 to 84 days
(anti-H. influenzae b and anti-tetanus, respectively.) The
half-lives of three antibodies to S. pneumoniae serotypes
were 41, 60, and 30 days [35].
The mean trough IgG levels were 1,076 ± 254 mg/dL
(range 606–1,780 mg/dL) in the 21-day patients and
943 ± 215 (range 487–2,250 mg/dL) in the 28-day
patients. The 487 mg/dL trough value was a single test
result reported at the sixth infusion in one patient [35].
Discussion
The 1999 BPAC meeting concluded that each IVIG is
unique and should not be treated as a single generic product
[1]. Consequently, the FDA proposed that phase III clinical
trials of new IVIGs (including licensed products with
modified manufacturing procedures) should be more rig-
orous than previous trials of small numbers of patients
[18–20]. It soon became apparent that the number of
patients with primary immunodeficiency that could be
recruited for IVIG clinical trials was too limited to support
the number of new IVIGs that needed to be tested. This
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prompted the analysis of possible IVIG trials that would
reduce the sample size.
A new proposal was to conduct a single-arm, 12-month,
open-label study with comparison to historical controls for
safety, pharmacokinetics, and efficacy endpoints. The FDA
defined infusional AEs as those that are temporally asso-
ciated with an IVIG infusion, i.e., occurred during or
within 72 h of an infusion. The safety endpoint was defined
as the proportion of infusions with one or more temporally
associated AEs (including AEs that are determined not to
be product-related). The target for this endpoint is an upper
one-sided 95 % confidence limit of \0.40 [4].
The efficacy endpoint is the incidence of SBIs. Based on
historical data, patients with primary humoral immunode-
ficiency experienced approximately 4 or more SBIs per
year prior to routine immunoglobulin therapy [4]. Also, the
SBI rate was \0.5 per year during periods of regular
immunoglobulin therapy (200–600 mg/kg/infusion, every
3 or 4 weeks) [4]. Accordingly, the FDA set an SBI target
of an upper one-sided 99 % confidence limit\1.0 SBI per
person per year. The criteria for diagnosing SBIs were
defined in the Guidance [4].
The safety and efficacy endpoints in the FDA IVIG
Guidances [3, 4] have essentially been incorporated into
each of the IVIG clinical trials published since 2004. The
trial that compared Gamunex 10 % to Gamimune N 10 %
used serious infection endpoints that were different from
the other studies.
Although many of the same study sites were involved in
studies of multiple products, the patient population in each
clinical trial is assumed to be different. However, the
majority (52 to 92 %) of patients in each study were
diagnosed with CVID. The proportion of XLA patients
varied from 0 to 28 % (Table 1).
The rate of SBIs (the primary efficacy endpoint) in each
study was well below the 0.5 per year reported by the FDA
as the historical frequency during periods of regular
immunoglobulin therapy [4]. SBI rates varied from 0 to
0.08 SBI/patient/year (Table 1). The rate of non-serious
infections also varied from study to study, with values of
1.96–3.55 infections/patient/year (Table 1).
Days of work and school missed because of PID-related
illness were reported in six studies and varied from an
average of 2.1 days/year (Biotest-IVIG) to 13 days/year
(Flebogamma 5 %). The values of 13 and 8.7 days of
missed work/school resulted from relatively few patients.
The average number of hospitalization days per year
caused by PID-related infections was low in each study,
ranging from 0.21 (Biotest-IVIG) to 2.31 (Privigen). The
studies that recorded unscheduled physician or ER visits
as an efficacy parameter reported mean values of 2
visits/patient/year (Octagam) to 5.6 visits/patient/year
(Gammaplex).
Antibiotic administration was reported in four studies
(Table 1). Therapeutic antibiotic days/patient/year were
very similar for the three studies that reported it. Prophy-
lactic antibiotics were reported as 81 days/patient/year in
the Flebogamma 5 % study and 46 days/patient/year in the
Flebogamma 10 % study. Two studies reported only the
total number of antibiotic days/patient/year—Privigen
(87.4 days) and Biotest-IVIG (82 days). Total antibiotic
days/patient/year in the Flebogamma 5 % and Fle-
bogamma 10 % studies were 136.7 and 103.8, respectively.
IgG half-life values ranged from 20 ± 4 days in the
Biotest-IVIG 21-day infusion group to 37 ± 13 days in the
Flebogamma 10 % 28-day infusion group. IgG half-lives
reported without segregation into infusion groups ranged
from 34 to 41 ± 17 days. When recorded, the half-lives of
IgG subclasses and specific antibodies were the essentially
the same as the total IgG. The lack of standardized test
procedures for determining specific antibody concentra-
tions renders the comparison of antibody trough and other
pharmacokinetic parameters difficult.
The reporting of AEs varied from study to study, with
temporally associated AEs varying from 30 min to 72 h
post-infusion. Using the 72-h time frame, the incidence of
infusions with one or more temporal AEs (regardless of
causality) produced AE rates of 20.1–47 % (Table 2). AEs
considered to be related to the study IVIG ranged from 5 %
of infusions for Octagam to 27.6 % of Flebogamma 10 %
infusions (Table 2). Headache was the most common AE
in every study.
The appearance of Coombs positivity after infusion of
the study IVIGs occurred in four clinical trials. The pro-
portion of patients that became Coombs-positive after
infusion varied from 8.5 to 47 %. However, none of the
patients in any of the trials developed evidence of hemo-
lysis or anemia.
Clinical results with the newest IVIG from Biotest
compared favorably to the results obtained with other
IVIGs. Investigators observed a relatively low incidence of
non-serious infections (2.6 per patient per year), few mis-
sed days of work/school (2.28 per patient per year), and a
low rate of hospitalizations (0.21 per patient per year). The
number of days of antibiotic treatment during the Biotest-
IVIG study (82 days) were also lower than reports from
other studies (range 87.4–136.7 days). AE rates were
comparable to the rates reported for other products.
In summary, a review of IVIG clinical trial results
reported in the new millennium show that clinical trial
protocols are becoming more and more standardized,
thanks to efforts of the FDA. Although comparisons should
be conducted cautiously, the standardization of clinical
trial data offers the opportunity to compare results from
study to study. If standardized tests for quantifying specific
antibodies are developed, pharmacokinetic studies may
Intravenous immunoglobulin replacement therapy 609
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provide more meaningful information with respect to
appropriate IVIG doses to prevent infection.
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